Our scientific advisory board is composed of renowned experts in the field of neurodegenerative disease research and clinical development.
Prof. Raymond G. Hill
Prof. Dr., Pharm., Ph.D, DSc (H.C.), FMedSci & Chair of Asceneuron SAB
Prof. Raymond G. Hill is currently Honorary Professor of Pharmacology, Faculty of Medicine Imperial College, London. He is part of a research group using fMRI to investigate whether substance P antagonism might help patients with opioid use disorder and teaches on postgraduate courses on drug discovery and translational pharmacology.
He started his career as a University academic active in teaching and research in Pharmacology (1974 to 1988). From 1990 until his retirement in 2008 he worked in drug discovery research for Merck / MSD. He was Executive Director, Pharmacology at the UK Neuroscience Research Centre engaged in drug discovery for Neuroscience indications, with global responsibility for Pain and Headache targets. He also (1997-2002) had oversight responsibility for Neuroscience research at the Banyu Research Labs in Tsukuba, Japan. He chaired a number of discovery project teams including those responsible for the marketed products Maxalt® and Emend®.
Dr Hill is Visiting Industrial Professor of Pharmacology in the University of Bristol and has been Visiting Professor at the University of Surrey and at Strathclyde University. He is President Emeritus British Pharmacological Society and was, among others, a Member of Council, Academy of Medical Sciences and a member of the UK Government Advisory Council on the Misuse of Drugs.
Dr Hill has published more than 250 peer reviewed papers on neuropharmacology. He is co-author (with J.A. Alexander) of a text book on Postoperative Pain Control and (with D Richards) of one on Drug Discovery and Development.
https://www.imperial.ac.uk/people/raymond.hill
Christian Haass
Prof. Dr. Dr.h.c.
Prof. Christian Haass heads the Department of Metabolic Biochemistry at the Adolf-Butenandt Institute at LMU Munich. He has been Coordinator of the German Center for Neurodegenerative Disorders (DZNE) in Munich since 2009. Dr. Haass made major discoveries between 1990-1995 showing how beta-amyloid peptide is generated at the cellular level in Alzheimer’s disease (AD) while working at the Center for Neurologic Diseases at Harvard Medical School where he was Assistant Professor for Neurology. He was Associate Professor for Molecular Biology at Central Institute of Mental Health, Mannheim (1995-1999) and Professor for Biochemistry at LMU Munich since 1999, where he has investigated the structure, function and amyloidogenesis of AD causing presenilin-dependent intramembrane protease complexes. Dr. Haass has received many awards for his innovative, high impact research.
www.biochemie.abi.med.uni-muenchen.de/haass/index.html
Adam Boxer
Prof. Dr.
Prof. Adam Boxer is Professor of Neurology and the Vera and John Graziadio Scholar in Alzheimer’s Disease Research at UCSF, where he directs the Alzheimer’s Disease and Frontotemporal Dementia Clinical Trials Program at the Memory and Aging Center. He was the lead principle investigator of the first US multicenter, randomized, placebo-controlled, clinical trial of a therapeutic agent for frontotemporal dementia (memantine/Namenda®) and an international, phase 2/3, randomized, placebo-controlled trial of the microtubule stabilizing agent, davunetide (NAP, Al-108), for PSP. He is principal Investigator of the NIH-funded, North American rare disease clinical research consortium, entitled Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL), which is dedicated to preparing for clinical trials in PSP and other FTLD-spectrum disorders.
Günter U. Höglinger
Prof. Dr.
Prof. Günter U. Höglinger heads the Institute for Translational Neurodegeneration of the DZNE (German Center for Neurodegenerative Diseases) and is Consultant Senior Neurologist at the Dept. of Neurology in the Klinikum rechts der Isar of the Technical University Munich, Germany. His present research focuses on the identification of environmental and genetic causes of neurodegenerative akinetic-rigid and dementing syndromes including progressive supranuclear palsy, the improvement of diagnostic tools and the development of therapeutic interventions. Günter Höglinger pioneered prior clinical therapeutic developments in PSP patients (Stamelou, M, et al., Mov Disord. 2008,23: 942-9; Höglinger, GU, et al., Mov. Disord. 2014;29: 479-87) and led the study that first identified genetic risk factors for PSP (Höglinger, GU, et al., Nature Genetics, 2011;43: 699-705). He studied Medicine and Physics at the Universities of Regensburg and Würzburg, Germany. He was Deputy Director of the Dept. of Neurology under Prof. Dr. Dr. W. H. Oertel at the Philipps University Marburg. He is member of the Scientific Advisory Board of the curePSP foundation and co-chair the SAB of the German PSP society.
